Skip to main content
Script Wolverine

A curated listing of the BPC-157 + TB-500 research record — every constituent finding, dosing parameter and regulatory-access fact filed as its own entry, with the compounding and 503A status surfaced up front.

Which paper belongs to the claim you read?

Where can you find the BPC-157 TB-500 references?

The original repair studies tested separate substances before sellers paired them. The papers let your doctor check who received each substance and what happened afterward.

Return to the animal and human findingsRead the questions about pharmacy permission

What does the number beside a finding point to?

The early BPC-157 TB-500 findings came from separate work on tissue protection and cell movement. A number beside a finding points to a paper or a page from FDA below.

I'd bring the claim and its number to your next doctor's visit. Your doctor can check which substance was given, who received the treatment, what improved, how long the benefit lasted, and whether the study found harm that matters to your own care.

Papers 1-2 and 12 concern BPC-157; papers 3-8 concern TB-500 and whole Thymosin Beta-4. Papers 9-11 discuss the few human findings and the lack of comparisons for mixing.

Entries 13-15 explain pharmacy ingredient rules and the FDA advisers' discussion. Your pharmacist can check those pages before explaining permission for the ingredients proposed for you.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. ↗
  6. Philp D, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387. ↗
  7. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. ↗
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; "no clinical safety data"; no mention of TB-500 or combination use.) ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for "BPC-157 (free base)" / "BPC-157 acetate" and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; effective with the September 29, 2023 list update.) ↗
  14. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (503A/503B framework; Category 1 and Category 2 definitions; bulks-list and PCAC nomination process.) ↗
  15. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public agenda listing BPC-157 and TB-500 among bulk drug substances "being considered for inclusion on the 503A Bulks List"; a discussion item, not a decision.) ↗
  16. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  17. Ho ENM, et al.. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  18. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  19. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗